Daiichi Awarded $46M Fees In Cancer Drug Patent Arbitration
Japanese drugmaker Daiichi Sankyo Ltd. has scored nearly $46 million in fees and costs in an arbitration initiated by rival Seagen in the companies' patent dispute over cancer drug technology after...To view the full article, register now.
Already a subscriber? Click here to view full article